Key Details
The draft amendments to the Medical Devices Rules, 2017 propose a risk-based acceleration of manufacturing licence approvals by prescribing shorter statutory timelines across higher-risk device categories while retaining the existing regulatory framework for Class A devices.
Device Class | Typical Risk | Examples | Current Timeline | Proposed Timeline |
|---|---|---|---|---|
Class A | Low risk | Surgical dressings, elastic bandages, tongue depressors | Fast-track notification route | No change |
Class B | Low to moderate risk | Blood pressure monitors, hypodermic needles, pulse oximeters | 140 days | 115 days |
Class C | Moderate to high risk | Ventilators, insulin pumps, bone fixation devices | 105 days | 90 days |
Class D | High risk / life-support | Cardiac stents, pacemakers, orthopaedic implants | 105 days | 90 days |
Summary
Draft Amendments Seek Faster Medical Device Approvals
The Ministry of Health and Family Welfare has published draft amendments to the Medical Devices Rules, 2017, proposing shorter statutory timelines for granting manufacturing licences for Class B, C and D medical devices. The proposal seeks to make India’s medical-device regulatory system more predictable and efficient while maintaining the existing risk-based regulatory framework that applies different levels of scrutiny according to the potential risks posed by a device.
Licensing Timelines Would Be Shortened Across Risk Categories
The draft proposes reducing the maximum approval period for Class B devices from 140 days to 115 days, while the timelines for Class C and D devices would be reduced from 105 days to 90 days. It also prescribes defined timelines for individual stages of the licensing process—including document scrutiny, inspections, third-party audits and final licence issuance—to minimise administrative delays and improve regulatory certainty for manufacturers.
Safety Standards Continue Under the Existing Risk-Based Framework
The amendments do not change India’s risk-based classification of medical devices or dilute regulatory oversight. Higher-risk products such as cardiac stents, pacemakers and ventilators will continue to undergo more rigorous evaluation than lower-risk products. The proposed reforms focus on improving the efficiency of regulatory processes rather than relaxing safety or quality requirements.
Draft Notification Opens Public Consultation
The notification has been placed in the public domain for stakeholder comments before being finalised. If adopted, the amendments could shorten the time required to establish new manufacturing capacity, improve regulatory predictability for medical-device companies and strengthen India’s domestic medical-device ecosystem while maintaining patient safety safeguards.
What is Risk-Based Device Classification?
India’s risk-based device classification groups medical devices into Class A, B, C and D based on the level of risk they pose to patients. Lower-risk devices generally face simpler regulatory requirements, while higher-risk products such as implantable or life-support devices undergo more extensive technical evaluation, inspections and regulatory scrutiny before manufacturing licences are granted.
Policy Relevance
Supports India’s efforts to strengthen domestic medical-device manufacturing by reducing regulatory delays and improving predictability for new manufacturing facilities.
Reinforces a risk-based regulatory approach, where administrative processes are streamlined without weakening safety standards for higher-risk medical devices.
Can accelerate the availability of domestic manufacturing capacity for critical medical devices, strengthening resilience across healthcare supply chains.
Improves the ease of doing business for medical-device manufacturers by introducing clearer statutory timelines for regulatory approvals.
Complements broader initiatives to reduce import dependence and expand India’s capabilities in high-value medical technology manufacturing.
Demonstrates how regulatory process reforms, alongside industrial and innovation policies, can improve the competitiveness of India’s medical-device sector while maintaining patient safety.
Relevant Question for Policy Stakeholders: As manufacturing licence timelines are shortened, what additional digital and institutional reforms within CDSCO will be needed to ensure that inspections, third-party audits and technical reviews are completed within statutory deadlines without compromising the quality of regulatory oversight?
Follow the Full Draft Notification Here: Amendments to Medical Devices Rules, 2017 to Streamline Licensing Process